ArticleLa Radiologia medica2018
Stereotactic body radiotherapy for oligometastatic soft tissue sarcoma.
Article in La Radiologia medica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Stereotactic Body Radiotherapy Without Systemic Therapy for Oligometastatic Cancer: A Systematic Review and Meta-Analysis.JAMA network open · 2025Pooled it
- SEOM Clinical Guideline of management of soft-tissue sarcoma (2020).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Guideline
- Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial.JAMA oncology · 2020Trial
- Review
- Lung Stereotactic Body Radiotherapy (SBRT) on Metastatic Sarcomas: A Retrospective Study at a Quaternary Center.Cureus · 2025Article
- Leiomyosarcoma Therapeutic Approaches and Future Directions.Hematology/oncology clinics of North America · 2025Review
- Article
- Efficacy of cystectomy in single-site oligometastatic bladder cancer: a Surveillance, Epidemiology, and End Results (SEER) study of 1,381 patients.Translational andrology and urology · 2025Article
- Review
- Stereotactic body radiotherapy for recurrent and oligometastatic soft tissue sarcoma.World journal of surgical oncology · 2022Review
- The Role of MRI-Guided Radiotherapy for Soft Tissue Sarcomas.Journal of clinical medicine · 2022Review
- Chemosensitivity of Lung Metastatic High-Grade Synovial Sarcoma.Journal of clinical medicine · 2021Article
- Review
- Article
- Long-term survival with multiple metastasectomies for pulmonary osteosarcoma: a case report.Surgical case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStereotactic body radiotherapy (SBRT) is emerging as a novel treatment option in metastatic soft tissue sarcoma (STS). The aim of our study was to evaluate the effectiveness of exclusive SBRT on disease control and survival in oligometastatic (≤ 3 synchronous lesions) STS. MATERIALS AND
methodsIn total, 16 consecutive patients, accounting for 26 metastases (including 21 lung and 5 lymph node or soft tissue metastases), were treated at our institution with SBRT. Patient- and treatment-related characteristics were collected. Local control (LC), overall survival (OS), distant metastases-free survival (DMFS), and time to initiation of chemotherapy or best supportive care (corrected disease-free survival, cDFS) were assessed.
resultsFour-year OS was 54% and median OS was 69 months [95% confidence interval (CI) 20-118 months]. LC of 26 lesions at 4 years was 78%. Median DMFS and cDFS were 17 (95% CI 5-30 months) and 28 months (95% CI 5-52 months), respectively. Disease-free interval < 24 months from primary tumor treatment to first metastasis was the only predictor of reduced LC, cDFS, and OS (p = 0.022, 0.023, and 0.028, respectively). No acute or chronic grade ≥ 3 toxicity was observed. Median follow-up was 36 months (IQR 18-71 months).
conclusionsIn patients with oligometastatic STS, SBRT yields satisfying local control with minimal toxicity. Median OS was 69 months. Repeated SBRT may be considered to extend disease-free and systemic therapy-free interval. Increased time from primary tumor to first metastasis identifies patients with potentially greater benefit from SBRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.